Structural and functional alterations of FLT3 in acute myeloid leukemia
about
How I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaOptimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaInternal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic LeReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersPim-1 kinase as cancer drug target: An updateSurvey of activated FLT3 signaling in leukemiaMitochondrial pathway mediates the antileukemic effects of Hemidesmus indicus, a promising botanical drugDistinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemiaDevelopment of Bioinformatics Pipeline for Analyzing Clinical Pediatric NGS Data.Identification of potent Yes1 kinase inhibitors using a library screening approach.Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).Discovery of a Diaminopyrimidine FLT3 Inhibitor Active against Acute Myeloid Leukemia.Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) CellsNiche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaThe class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic interventionC/EBPα and MYB regulate FLT3 expression in AMLMutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplicationLeukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology GroupInhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignanciesPotent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia inductionA growing family: adding mutated Erbb4 as a novel cancer targetTreatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsSelective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.Co-culture with podoplanin+ cells protects leukemic blast cells with leukemia-associated antigens in the tumor microenvironment.Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programFLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cellsDifferential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.Molecular diagnosis of acute myeloid leukemia.
P2860
Q26992280-C9519BF1-4083-4E14-A17C-1846B5B58F70Q27005960-46398A1F-841D-4130-93BC-1B26313D2439Q27674324-FFB06E4D-EA10-487D-A457-9539720D951DQ27853031-E583718F-8868-42CD-BDF2-275C58525ACEQ28082793-B5A8352E-61BE-44E0-B6E2-4B85895DABD6Q28273475-299F0FD2-6002-438C-AF6E-CE57F1DFB0CAQ28477934-7CC38D01-9E1D-43C7-BB85-0C4BE8D0A820Q28478861-64BEE629-93A3-417D-8871-D81C09ED2D9CQ28749564-582AA02C-7C76-4124-96F7-A88FF46C6B91Q30989707-CE9BA297-F1F7-4CC5-8008-8AA6B5D80A93Q31119738-BF598D28-B305-438E-90A6-BE5BD01067F6Q33637691-A206D6F1-30D9-4DFD-AEF2-08661F8B691FQ33737486-05F81B9D-0F1F-4C50-9F0B-41B2EEEE3193Q33749036-F7EAC440-D89C-47BD-80C6-DC7F70EEBBE9Q33882022-A961A92C-3B8B-4BEA-BD27-81A69C899E10Q33886530-F0D7DB5D-487B-41BE-9560-56294BDD54A3Q33913329-B0DDE267-F4CE-4D6F-BBFA-986D1364DFC6Q34286759-3E6F5948-F57A-46EB-9992-EA8E9499E634Q34425939-34A42BFD-0895-4B99-972E-7FA69CC7BCBBQ34682013-1837AA07-1B34-468B-93D4-FF766FF9F0B8Q34990221-6D0C3517-B6DB-4F34-B5FE-E9C1D1606C46Q35046171-4E7EB8D6-F1AD-41DB-87E2-F1B1D5181473Q35048469-9419C93F-0FD8-4985-B180-21AE0EF9FCB4Q35125923-23311761-C2F6-466A-889C-BFFE8709B5A5Q35172210-92025074-C604-4C0A-89FA-714A921338A5Q35608465-B9354352-5001-423D-83B4-96247E1C6781Q36036310-0B810548-EB95-4F32-867C-60DB5706EADBQ36062442-C8D65B35-DBC2-42D4-B7A3-B813E5C5C533Q36220730-AF583536-03DC-4822-861F-85DE6EC0C6D8Q36276942-D5ADACC5-3DCD-485B-8DF6-2931B2FDC5BAQ36390379-9DC3218C-8840-4C05-BEE0-E7C63D45FF76Q36400942-5F7D6FA5-3ABE-4A23-8202-9B541C2D3C9BQ36469916-EEBD670A-4B74-46D0-AAF8-0C53A79678D8Q36758390-BA6C4AFF-38E1-43B5-A801-F2D6CB43B32EQ36817324-97E13727-8C15-41F7-8EB1-4354AA824AFAQ37295112-A9255B46-49F3-4AE2-9EBE-1DE150C82B3BQ37421401-6E45987B-CE4F-4391-B6C5-AF9075E635F0Q37535249-1A4934B6-5AE5-4262-B82C-94E5CD7EEFB0Q37647046-F4287F67-4AEC-495D-92B8-275B5A166942Q37809866-1FEC6AAD-5ED7-4337-8230-AEB7A455AC4B
P2860
Structural and functional alterations of FLT3 in acute myeloid leukemia
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Structural and functional alterations of FLT3 in acute myeloid leukemia
@ast
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en-gb
Structural and functional alterations of FLT3 in acute myeloid leukemia
@nl
type
label
Structural and functional alterations of FLT3 in acute myeloid leukemia
@ast
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en-gb
Structural and functional alterations of FLT3 in acute myeloid leukemia
@nl
prefLabel
Structural and functional alterations of FLT3 in acute myeloid leukemia
@ast
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en-gb
Structural and functional alterations of FLT3 in acute myeloid leukemia
@nl
P2860
P921
P1476
Structural and functional alterations of FLT3 in acute myeloid leukemia
@en
P2093
Soheil Meshinchi
P2860
P304
P356
10.1158/1078-0432.CCR-08-1123
P407
P577
2009-07-01T00:00:00Z